Robert J. Gould - 27 Jun 2023 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Interim President & CEO, Director
Signature
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould
Issuer symbol
FULC
Transactions as of
27 Jun 2023
Net transactions value
$0
Form type
4
Filing time
29 Jun 2023, 16:16:13 UTC
Previous filing
13 Jan 2023
Next filing
20 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 27 Jun 2023 Common Stock 30,000 $3.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.